Headlands Research, a North American trial site operator, has tapped Kyle Burtnett to lead the company, replacing Cathy Collins, who has been serving as interim CEO.
Burtnett joins Headlands after serving as president of GI Alliance, a network of gastroenterology specialists. Collins will remain at Headlands as a board member and in an advisory role to Burtnett, the company said in a June 28 press release. Burtnett’s appointment becomes effective July 3.
While at GI Alliance, Burtnett helped the company’s rapid growth and its recapitalization to reach a $2.2 billion valuation. Before GI Alliance, he held a number of leadership roles during 17 years at Tenet Healthcare.
Headlands has been on an expansion tear of late. In April, the company announced the acquisition of a research site in Massachusetts specializing in neurodegenerative diseases. That deal followed news in March that the trial operator opened a Detroit area clinical research site to help expand clinical trial access for underserved and underrepresented patients.
Just over a year ago, Headlands teamed with Pfizer to open new research sites to diversify clinical trials.